- Provides an in-depth understanding of the underlying concepts of Quality by Design (QbD) and the practical aspects of the implementation of QbD in biopharmaceutical manufacturing. - Outlines the critical quality attributes for the molecule, development of the design space to meet the quality attributes, filing of the QbD information in regulatory documents, risk management and the application of QbD for routine manufacturing - Case studies are provided e to further enhance the understanding of QbD and provide the reader with "real-world" examples of its various aspects This is the first…mehr
- Provides an in-depth understanding of the underlying concepts of Quality by Design (QbD) and the practical aspects of the implementation of QbD in biopharmaceutical manufacturing. - Outlines the critical quality attributes for the molecule, development of the design space to meet the quality attributes, filing of the QbD information in regulatory documents, risk management and the application of QbD for routine manufacturing - Case studies are provided e to further enhance the understanding of QbD and provide the reader with "real-world" examples of its various aspectsThis is the first book that explains the underlying concepts of Quality by Design (QbD) and the practical aspects of implementing QbD in biopharmaceutical manufacturing. A systematic approach leads the reader through a process, outlining the understanding of the critical quality attributes of the molecule, the development of the design space to meet the quality attributes, filing of the QbD information in regulatory documents, risk management, and the application of QbD. Complete with real world case studies, this is a core reference for scientists in the biopharmaceutical industry, regulatory agencies, and students.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Anurag S. Rathore received his PhD in chemical engineering from Yale University and is the Director of Process Development, Amgen Inc. His areas of interest include process development, scale-up, technology transfer, process validation, process analytical technology, and quality by design. He has authored more than 100 publications and presentations in these areas and serves on the editorial advisory boards for Biotechnology Progress, BioPharm International, Pharmaceutical Technology Europe, Journal of Biochemical and Biophysical Methods, and Separation and Purification Reviews. Rohin Mhatre is a Senior Director in the BioProcess Development department at Biogen Idec, Cambridge, Massachusetts, and has been with the company since 1996. His group is responsible for development of analytical methods and product characterization to support the process and formulation development of early and late stage clinical programs. Mhatre is also leading the QbD initiative within Biogen Idec. He has authored several publications and been an invited speaker to numerous scientific meetings.
Inhaltsangabe
Foreword xiii Preface xv Preface to the Wiley Series on Biotechnology and Related Topics xvii Contributors xix 1 QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS 1 Rohin Mhatre and Anurag S. Rathore 1.1 Introduction 1 1.2 Critical Quality Attributes 2 1.3 An Overview of Design Space 3 1.4 Raw Materials and their Impact on QbD 4 1.5 Process Analytical Technology 4 1.6 The Utility of Design Space and QbD 5 1.7 Conclusions 7 2 CONSIDERATIONS FOR BIOTECHNOLOGY PRODUCT QUALITY BY DESIGN 9 Steven Kozlowski and Patrick Swann 2.1 Introduction 9 2.2 Quality by Design 10 2.3 Relevant Product Attributes 11 2.4 Manufacturing Process 14 2.5 Developing a Design Space 18 2.6 Uncertainty and Complexity 22 2.7 Future Horizons 23 2.8 QbD Submission Thoughts 25 2.9 Implementation Plans 26 2.10 Summary 27 3 MOLECULAR DESIGN OF RECOMBINANT MALARIA VACCINES EXPRESSED BY Pichia pastoris 31 David L. Narum 3.1 Introduction 31 3.2 The Malaria Genome and Proteome 34 3.3 Expression of Two Malaria Antigens in P. pastoris 34 3.4 Summary 46 4 USING A RISK ASSESSMENT PROCESS TO DETERMINE CRITICALITY OF PRODUCT QUALITY ATTRIBUTES 53 Mark A Schenerman, Milton J. Axley, Cynthia N. Oliver, Kripa Ram, and Gail F. Wasserman 4.1 Introduction 53 4.2 Examples of Criticality Determination 60 4.3 Conclusion 81 5 CASE STUDY ON DEFINITION OF PROCESS DESIGN SPACE FOR A MICROBIAL FERMENTATION STEP 85 Pim van Hoek, Jean Harms, Xiangyang Wang, and Anurag S. Rathore 5.1 Introduction 85 5.2 Approach Toward Process Characterization 87 5.3 Risk Analysis 88 5.4 Small-Scale Model Development and Qualification 89 5.5 Design of Experiment Studies 94 5.6 Worst Case Studies 96 5.7 Definition of Design Space 99 5.8 Definition of Validation Acceptance Limits 103 5.9 Regulatory Filing, Process Monitoring, and Postapproval Changes 106 6 APPLICATION OF QbD PRINCIPLES TO TANGENTIAL FLOW FILTRATION OPERATIONS 111 Peter K. Watler and John Rozembersky 6.1 Introduction 111 6.2 Applications of TFF in Biotechnology 113 6.3 Tangential Flow Filtration Operating Principles 113 6.4 TFF Design Objectives 115 6.5 Membrane Selection 115 6.6 TFF Operating Parameter Design 118 6.7 TFF Diafiltration Operating Mode Design 122 6.8 Summary 125 7 APPLICATIONS OF DESIGN SPACE FOR BIOPHARMACEUTICAL PURIFICATION PROCESSES 127 Douglas J. Cecchini 7.1 Introduction 127 7.2 Establishing Design Space for Purification Processes during Process Development 128 7.3 Applications of Design Space 131 7.4 Cell Harvest and Product Capture Steps 131 7.5 Protein A Capture Column 136 7.6 Hydrophobic Interaction Chromatography 137 7.7 Anion Exchange Chromatography 138 7.8 Summary 141 8 VIRAL CLEARANCE: A STRATEGY FOR QUALITY BY DESIGN AND THE DESIGN SPACE 143 Gail Sofer and Jeffrey Carter 8.1 Introduction 143 8.2 Current and Future Approaches to Virus Clearance Characterization 143 8.3 Benefits of Applying Design Space Principles to Virus Clearance 144 8.4 Technical Limitations Related to Adoption of QdB/Design Space Concepts in Virus Clearance 145 8.5 Developing a Virus Clearance Design Space 148 8.6 Staying in the Design Space 156 8.7 Conclusion 157 9 APPLICATION OF QUALITY BY DESIGN AND RISK ASSESSMENT PRINCIPLES FOR THE DEVELOPMENT OF FORMULATION DESIGN SPACE 161 Kingman Ng and Natarajan Rajagopalan 9.1 Introduction 161 9.2 Quality by Design (QbD) Approach 162 9.3 Target Product Profile (TPP) 163 9.4 Molecular Degradation Characterization 164 9.5 Active Pharmaceutical Ingredient (API) Critical Properties 166 9.6 Preformulation Characterization 167 9.7 Initial Formulation Risk Assessments 168 9.8 Formulation Optimization and Design Space 169 9.9 Selection of Solution Formulation Composition 171 9.10 Summary 173 10 APPLICATION OF QbD PRINCIPLES TO BIOLOGICS PRODUCT: FORMULATION AND PROCESS DEVELOPMENT 175 Satish K. Singh, Carol F. Kirchhoff, and Amit Banerjee 10.1 Introduction: QbD in Biologics Product Development 175 10.2 Risk Assessment Process 177 10.3 Examples 178 10.4 Conclusions 191 11 QbD FOR RAW MATERIALS 193 Maureen Lanan 11.1 Introduction 193 11.2 Background 194 11.3 Current Practice for Raw Materials 195 11.4 QbD in Development 195 11.5 QbD in manufacturing 196 11.6 QbD for organizations 197 11.7 Tests Available 197 11.8 Conclusions and Future Prospects 207 12 PAT TOOLS FOR BIOLOGICS: CONSIDERATIONS AND CHALLENGES 211 Michael Molony and Cenk Undey 12.1 Introduction 211 12.2 Cell Culture and Fermentation PAT Tools 214 12.3 Purification PAT Tools 223 12.4 Formulation PAT Tools 228 12.5 PAT Tools for Bioprocess Starting Materials, Defined Media, and Complex Raw Materials 230 12.6 Chemometrics and Advanced Process Control Tools 232 12.7 The power of PLS and PCA 233 12.8 "Relevant Time"Column Integrity Monitoring (Moments Analysis versus HETP) 240 12.9 Challenges for Implementation of PAT Tools 244 12.10 Future PAT Tools 247 13 EVOLUTION AND INTEGRATION OF QUALITY BY DESIGN AND PROCESS ANALYTICAL TECHNOLOGY 255 Duncan Low and Joseph Phillips 13.1 Introduction 255 13.2 Evolution of PAT and Quality by Design (QbD): Emerging Guidelines and Standards 256 13.3 Process Analytical Technology (PAT) 261 13.4 Quality by Design 263 13.5 Implementing QbD and PAT 266 13.6 Conclusions 282 Acknowledgments 283 References 283 Index 287
Foreword xiii Preface xv Preface to the Wiley Series on Biotechnology and Related Topics xvii Contributors xix 1 QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS 1 Rohin Mhatre and Anurag S. Rathore 1.1 Introduction 1 1.2 Critical Quality Attributes 2 1.3 An Overview of Design Space 3 1.4 Raw Materials and their Impact on QbD 4 1.5 Process Analytical Technology 4 1.6 The Utility of Design Space and QbD 5 1.7 Conclusions 7 2 CONSIDERATIONS FOR BIOTECHNOLOGY PRODUCT QUALITY BY DESIGN 9 Steven Kozlowski and Patrick Swann 2.1 Introduction 9 2.2 Quality by Design 10 2.3 Relevant Product Attributes 11 2.4 Manufacturing Process 14 2.5 Developing a Design Space 18 2.6 Uncertainty and Complexity 22 2.7 Future Horizons 23 2.8 QbD Submission Thoughts 25 2.9 Implementation Plans 26 2.10 Summary 27 3 MOLECULAR DESIGN OF RECOMBINANT MALARIA VACCINES EXPRESSED BY Pichia pastoris 31 David L. Narum 3.1 Introduction 31 3.2 The Malaria Genome and Proteome 34 3.3 Expression of Two Malaria Antigens in P. pastoris 34 3.4 Summary 46 4 USING A RISK ASSESSMENT PROCESS TO DETERMINE CRITICALITY OF PRODUCT QUALITY ATTRIBUTES 53 Mark A Schenerman, Milton J. Axley, Cynthia N. Oliver, Kripa Ram, and Gail F. Wasserman 4.1 Introduction 53 4.2 Examples of Criticality Determination 60 4.3 Conclusion 81 5 CASE STUDY ON DEFINITION OF PROCESS DESIGN SPACE FOR A MICROBIAL FERMENTATION STEP 85 Pim van Hoek, Jean Harms, Xiangyang Wang, and Anurag S. Rathore 5.1 Introduction 85 5.2 Approach Toward Process Characterization 87 5.3 Risk Analysis 88 5.4 Small-Scale Model Development and Qualification 89 5.5 Design of Experiment Studies 94 5.6 Worst Case Studies 96 5.7 Definition of Design Space 99 5.8 Definition of Validation Acceptance Limits 103 5.9 Regulatory Filing, Process Monitoring, and Postapproval Changes 106 6 APPLICATION OF QbD PRINCIPLES TO TANGENTIAL FLOW FILTRATION OPERATIONS 111 Peter K. Watler and John Rozembersky 6.1 Introduction 111 6.2 Applications of TFF in Biotechnology 113 6.3 Tangential Flow Filtration Operating Principles 113 6.4 TFF Design Objectives 115 6.5 Membrane Selection 115 6.6 TFF Operating Parameter Design 118 6.7 TFF Diafiltration Operating Mode Design 122 6.8 Summary 125 7 APPLICATIONS OF DESIGN SPACE FOR BIOPHARMACEUTICAL PURIFICATION PROCESSES 127 Douglas J. Cecchini 7.1 Introduction 127 7.2 Establishing Design Space for Purification Processes during Process Development 128 7.3 Applications of Design Space 131 7.4 Cell Harvest and Product Capture Steps 131 7.5 Protein A Capture Column 136 7.6 Hydrophobic Interaction Chromatography 137 7.7 Anion Exchange Chromatography 138 7.8 Summary 141 8 VIRAL CLEARANCE: A STRATEGY FOR QUALITY BY DESIGN AND THE DESIGN SPACE 143 Gail Sofer and Jeffrey Carter 8.1 Introduction 143 8.2 Current and Future Approaches to Virus Clearance Characterization 143 8.3 Benefits of Applying Design Space Principles to Virus Clearance 144 8.4 Technical Limitations Related to Adoption of QdB/Design Space Concepts in Virus Clearance 145 8.5 Developing a Virus Clearance Design Space 148 8.6 Staying in the Design Space 156 8.7 Conclusion 157 9 APPLICATION OF QUALITY BY DESIGN AND RISK ASSESSMENT PRINCIPLES FOR THE DEVELOPMENT OF FORMULATION DESIGN SPACE 161 Kingman Ng and Natarajan Rajagopalan 9.1 Introduction 161 9.2 Quality by Design (QbD) Approach 162 9.3 Target Product Profile (TPP) 163 9.4 Molecular Degradation Characterization 164 9.5 Active Pharmaceutical Ingredient (API) Critical Properties 166 9.6 Preformulation Characterization 167 9.7 Initial Formulation Risk Assessments 168 9.8 Formulation Optimization and Design Space 169 9.9 Selection of Solution Formulation Composition 171 9.10 Summary 173 10 APPLICATION OF QbD PRINCIPLES TO BIOLOGICS PRODUCT: FORMULATION AND PROCESS DEVELOPMENT 175 Satish K. Singh, Carol F. Kirchhoff, and Amit Banerjee 10.1 Introduction: QbD in Biologics Product Development 175 10.2 Risk Assessment Process 177 10.3 Examples 178 10.4 Conclusions 191 11 QbD FOR RAW MATERIALS 193 Maureen Lanan 11.1 Introduction 193 11.2 Background 194 11.3 Current Practice for Raw Materials 195 11.4 QbD in Development 195 11.5 QbD in manufacturing 196 11.6 QbD for organizations 197 11.7 Tests Available 197 11.8 Conclusions and Future Prospects 207 12 PAT TOOLS FOR BIOLOGICS: CONSIDERATIONS AND CHALLENGES 211 Michael Molony and Cenk Undey 12.1 Introduction 211 12.2 Cell Culture and Fermentation PAT Tools 214 12.3 Purification PAT Tools 223 12.4 Formulation PAT Tools 228 12.5 PAT Tools for Bioprocess Starting Materials, Defined Media, and Complex Raw Materials 230 12.6 Chemometrics and Advanced Process Control Tools 232 12.7 The power of PLS and PCA 233 12.8 "Relevant Time"Column Integrity Monitoring (Moments Analysis versus HETP) 240 12.9 Challenges for Implementation of PAT Tools 244 12.10 Future PAT Tools 247 13 EVOLUTION AND INTEGRATION OF QUALITY BY DESIGN AND PROCESS ANALYTICAL TECHNOLOGY 255 Duncan Low and Joseph Phillips 13.1 Introduction 255 13.2 Evolution of PAT and Quality by Design (QbD): Emerging Guidelines and Standards 256 13.3 Process Analytical Technology (PAT) 261 13.4 Quality by Design 263 13.5 Implementing QbD and PAT 266 13.6 Conclusions 282 Acknowledgments 283 References 283 Index 287
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
